COST-UTILITY ANALYSIS OF 10-AND 13-VALENT PNEUMOCOCOCCAL CONJUGATE VACCINES IN THE PHILIPPINES

被引：0
|
作者：
Haasis, M. A. [1 ]
Ceria, J. A. [1 ]
机构：
[1] Dept Hlth, Manila, Philippines
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.526
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN26
引用
收藏
页码：A807 / A807
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine compared to the 10-valent vaccine in children: predictive analysis in the Ecuadorian context
    Bolanos-Diaz, Rafael
    Mino-Leon, Greta
    Zea, Eduardo
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2022, 13 (04) : 341 - 350
  • [42] COST-UTILITY ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE IMMUNIZATION OF CHILDREN UNDER FIVE YEARS FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Alexandre, R. F.
    Almeida, P.
    Sebastiao, M.
    Ferreira, P.
    Senna, T.
    VALUE IN HEALTH, 2023, 26 (06) : S77 - S77
  • [43] Cost-Effectiveness of a 10-Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden
    Klok, Rogier M.
    Lindkvist, Rose-Marie
    Ekelund, Mats
    Farkouh, Raymond A.
    Strutton, David R.
    CLINICAL THERAPEUTICS, 2013, 35 (02) : 119 - 134
  • [44] Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
    Vojicic, Jelena
    Grajales, Ana Gabriela
    Cane, Alejandro
    VACCINE, 2023, 41 (27) : 3949 - 3950
  • [45] Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia
    Urbancikova, Ingrid
    Prymula, Roman
    Goldblatt, David
    Roalfe, Lucy
    Prymulova, Karolina
    Kosina, Pavel
    VACCINE, 2017, 35 (38) : 5186 - 5193
  • [46] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
  • [47] Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
    Ricketson, Leah J.
    Bettinger, Julie A.
    Sadarangani, Manish
    Halperin, Scott A.
    Kellner, James D.
    VACCINE, 2022, 40 (19) : 2733 - 2740
  • [48] Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
    Zhou, Hua
    He, Jinchun
    Wu, Bin
    Che, Datian
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (06) : 1444 - 1452
  • [49] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Jaime E Ordóñez
    John J Orozco
    BMC Infectious Diseases, 14
  • [50] CLINICAL AND ECONOMIC BENEFITS OF NATIONAL IMMUNIZATION WITH THE 13-VALENT COMPARED TO 7-AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN GREECE
    Papanicolaou, S.
    Kontodimas, S.
    Syriopoulou, V
    Tsolia, M.
    Theodoridou, M.
    Strutton, D. R.
    Hwang, S.
    Tzanakaki, G.
    Kremastinou, J.
    Earnshaw, S. R.
    Farkouh, R.
    Karokis, A.
    Konstantopoulos, A.
    VALUE IN HEALTH, 2009, 12 (07) : A423 - A424
12345